KLAYESTA
RxNorm 646456· NYSTATIN TOPICAL POWDER· TOPICAL
Polyene Antifungal [EPC] · Epic Pharma, LLC
Indications and usage
INDICATIONS AND USAGE KLAYESTA is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. KLAYESTA is not indicated for systemic, oral, intravaginal or ophthalmic use.
Dosage and administration
DOSAGE AND ADMINISTRATION Very moist lesions are best treated with the topical dusting powder. Adults and Pediatric Patients (Neonates and Older) Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.
Contraindications
CONTRAINDICATIONS KLAYESTA is contraindicated in patients with a history of hypersensitivity to any of its components.
Pregnancy
Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with any KLAYESTA topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. KLAYESTA should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.
Nursing mothers
Nursing Mothers It is not known whether KLAYESTA is excreted in human milk. Caution should be exercised when KLAYESTA is prescribed for a nursing woman.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- fall3
- asthenia2
- confusional state2
- femur fracture2
- head injury2
- hypoglycaemia2
- loss of consciousness2
- nausea2
- pneumonia2
- product dose omission issue2
- pyrexia2
- sepsis2
- thrombocytopenia2
- anaemia1
- arthralgia1
- atrial fibrillation1
Adverse reactions (label)
ADVERSE REACTIONS The frequency of adverse events reported in patients using KLAYESTA is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS, General .)
View more: Full FDA label on DailyMed →Label effective 20251217